keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer ad

keyword
https://www.readbyqxmd.com/read/28543069/real-time-dynamic-mr-image-reconstruction-using-compressed-sensing-and-principal-component-analysis-cs-pca-demonstration-in-lung-tumor-tracking
#1
Bryson Dietz, Eugene Yip, Jihyun Yun, B Gino Fallone, Keith Wachowicz
PURPOSE: This work presents a real-time dynamic image reconstruction technique, that combines compressed sensing and principal component analysis (CS-PCA), to achieve real-time adaptive radiotherapy with the use of a linac-magnetic resonance imaging system. METHODS: Six retrospective fully sampled dynamic data sets of patients diagnosed with non-small cell lung cancer were used to investigate the CS-PCA algorithm. Using a database of fully sampled k-space, principal components (PC's) were calculated to aid in the reconstruction of undersampled images...
May 19, 2017: Medical Physics
https://www.readbyqxmd.com/read/28541925/improvement-screening-for-ultra-high-dimensional-data-with-censored-survival-outcomes-and-varying-coefficients
#2
Mu Yue, Jialiang Li
Motivated by risk prediction studies with ultra-high dimensional bio markers, we propose a novel improvement screening methodology. Accurate risk prediction can be quite useful for patient treatment selection, prevention strategy or disease management in evidence-based medicine. The question of how to choose new markers in addition to the conventional ones is especially important. In the past decade, a number of new measures for quantifying the added value from the new markers were proposed, among which the integrated discrimination improvement (IDI) and net reclassification improvement (NRI) stand out...
May 18, 2017: International Journal of Biostatistics
https://www.readbyqxmd.com/read/28537761/correlation-analysis-of-18-f-fluorodeoxyglucose-and-18-f-fluoroazomycin-arabinoside-uptake-distributions-in-lung-tumours-during-radiation-therapy
#3
Dario Di Perri, John A Lee, Anne Bol, François-Xavier Hanin, Guillaume Janssens, Daniel Labar, Annie Robert, Edmond Sterpin, Xavier Geets
BACKGROUND: PET-guided dose painting (DP) aims to target radioresistant tumour regions in order to improve radiotherapy (RT) outcome. Besides the well-known [(18)F]fluorodeoxyglucose (FDG), the hypoxia positron emission tomography (PET) tracer [(18)F]fluoroazomycin arabinoside (FAZA) could provide further useful information to guide the radiation dose prescription. In this study, we compare the spatial distributions of FDG and FAZA PET uptakes in lung tumours. MATERIAL AND METHODS: Fourteen patients with unresectable lung cancer underwent FDG and FAZA 4D-PET/CT on consecutive days at three time-points: prior to RT (pre), and during the second (w2), and the third (w3) weeks of RT...
May 24, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28515157/carboxyamidotriazole-synergizes-with-sorafenib-to-combat-non-small-cell-lung-cancer-through-inhibition-of-nanog-and-aggravation-of-apoptosis
#4
Chen Chen, Rui Ju, Jing Shi, Wei Chen, Fangrui Sun, Lei Zhu, Juan Li, Dechang Zhang, Caiying Ye, Lei Guo
Lung cancer is the leading cause of cancer-related deaths in the world. In this study, we investigated the combination of carboxyamidotriazole (CAI) and sorafenib in NSCLC in vitro and in vivo, to test whether CAI enhances the antitumor effects of sorafenib and reduces its side effects. The combination index (CI) showed that co-administration of CAI and sorafenib synergistically inhibited the proliferation of NSCLC cells (Lewis lung carcinoma, A549, NCI-H1975). The cell death led by the treatment of combination drugs was attributed to apoptosis which was accompanied with activation of caspase 3 and poly ADP-ribose polymerase...
May 17, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28503166/inhibition-of-ectopic-arginine-vasopressin-production-by-phenytoin-in-the-small-cell-lung-cancer-cell-line-lu-165
#5
Takahiro Ohta, Mitsuo Mita, Shigeru Hishinuma, Reiko Ishii-Nozawa, Kazuhisa Takahashi, Masaru Shoji
Phenytoin, a voltage-gated sodium channel (NaV channel) antagonist, reportedly inhibits arginine vasopressin (AVP) release from an isolated rat neurohypophysis. So far, it is uncertain whether phenytoin has a direct action on ectopic AVP-producing neuroendocrine tumors. We studied the effect of phenytoin on the release of copeptin, the C-terminal fragment of pro-AVP, and expression of AVP gene in the human small cell lung cancer cell line Lu-165. Cells were maintained in RPMI1640 medium with 10% fetal bovine serum and were used within the fifth passage...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/28503070/tyrosine-kinase-inhibitor-combination-therapy-in-first-line-treatment-of-non-small-cell-lung-cancer-systematic-review-and-network-meta-analysis
#6
Sarah Batson, Stephen A Mitchell, Ricarda Windisch, Elisabetta Damonte, Veronica C Munk, Noemi Reguart
INTRODUCTION: The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung cancer (NSCLC) with EGFR+ mutations. However, most patients develop resistance, with the result that median progression-free survival (PFS) iŝ12 months. Combining EGFR-TKIs with other agents, such as bevacizumab, is a promising approach to prolonging remission. This systematic review and network meta-analysis (NMA) were undertaken to assess available evidence regarding the benefits of first-line combination therapy involving EGFR-TKIs in patients with advanced NSCLC...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28497423/validation-of-the-prognostic-value-of-new-sub-stages-within-the-ajcc-8th-edition-of-non-small-cell-lung-cancer
#7
O Abdel-Rahman
BACKGROUND: The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study tried to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database. METHODS: SEER database (2010-2013) has been accessed through SEER*Stat program and AJCC 8th edition stages were reconstructed utilizing the collaborative stage descriptions...
May 11, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28475414/characterization-and-antitumor-efficacy-of-poly-l-lactid-acid-based-etoposide-loaded-implants
#8
Li Gao, Chuanqi Xie, Yuzhi Du, Xiaodong Wang, Erkang Xuan, Xiuxiu Liu, Yang Zhao, Jianjian Xu, Lan Luo
Etoposide is widely used in the chemotherapy of a variety of malignancies. But the strong lipophilicity, poor bioavailability, and severe side effects of etoposide limit its clinical application. The aim of this study was to develop sustained-release etoposide-loaded implants and evaluate antitumor activity of the implants after intratumoral implantation. We prepared the implants containing etoposide, poly(L-lactid acid) and polyethylene glycol 4000 by the direct compression method. The implants were characterized regarding drug-excipient compatibility, content uniformity, morphology, sterility, in vitro, and in vivo release profiles...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28468947/phase-i-trial-of-intratumoral-injection-of-ccl21-gene-modified-dendritic-cells-in-lung-cancer-elicits-tumor-specific-immune-responses-and-cd8-t-cell-infiltration
#9
Jay Moon M Lee, Mi-Heon Lee, Edward Garon, Jonathan W Goldman, Ramin Salehi-Rad, Felicita E Baratelli, Dorthe Schaue, Gerald Wang, Fran Rosen, Jane Yanagawa, Tonya C Walser, Ying Lin, Stacy J Park, Sharon Adams, Francesco M Marincola, Paul C Tumeh, Fereidoun Abtin, Robert Suh, Karen L Reckamp, Gina Lee, William D Wallace, Sarah Lee, Gang Zeng, David A Elashoff, Sherven Sharma, Steven M Dubinett
PURPOSE: A phase I study was conducted to determine safety, clinical efficacy, and anti-tumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral (IT) administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the CCL21 gene (Ad-CCL21-DC). We evaluated safety and tumor antigen-specific immune responses following in situ vaccination (ClinicalTrials.gov: NCT01574222). EXPERIMENTAL DESIGN: Sixteen stage IIIB/IV NSCLC subjects received two vaccinations (1 x 106, 5 x 106, 1 x 107, or 3 x 107 dendritic cells/injection) by CT- or bronchoscopic-guided IT injections (days 0 and 7)...
May 3, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28464441/current-studies-of-immunotherapy-in-head-and-neck-cancer
#10
Volkan Dogan, Thorsten Rieckmann, Adrian Münscher, Chia-Jung Busch
BACKGROUND: Recently enormous progress in cancer therapy has been achieved by the use of immune checkpoint inhibitors. Activating the body's own immune system has added a novel and powerful therapeutic option for the treatment of melanoma and lung cancer. Furthermore, the potential use of immunotherapy is being extensively explored also in other malignancies. OBJECTIVE OF REVIEW: This review summarizes current clinical studies using immune checkpoint modulators for the treatment of head and neck cancer (HNSCC)...
May 2, 2017: Clinical Otolaryngology
https://www.readbyqxmd.com/read/28464316/imaging-features-from-pre-treatment-ct-scans-are-associated-with-clinical-outcomes-in-non-small-cell-lung-cancer-patients-treated-with-stereotactic-body-radiotherapy
#11
Qian Li, Jongphil Kim, Yoganand Balagurunathan, Ying Liu, Kujtim Latifi, Olya Stringfield, Alberto Garcia, Eduardo G Moros, Thomas J Dilling, Matthew B Schabath, Zhaoxiang Ye, Robert J Gillies
PURPOSE: To investigate whether imaging features from pre-treatment planning CT scans are associated with overall survival (OS), recurrence-free survival (RFS), and loco-regional recurrence-free survival (LR-RFS) after stereotactic body radiotherapy (SBRT) among non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: A total of 92 patients (median age: 73 years) with stage I or IIA NSCLC were qualified for this study. A total dose of 50 Gy in 5 fractions was the standard treatment...
May 2, 2017: Medical Physics
https://www.readbyqxmd.com/read/28463164/individualized-selection-of-beam-angles-and-treatment-isocenter-in-tangential-breast-intensity-modulated-radiation-therapy
#12
Joan Penninkhof, Sara Spadola, Sebastiaan Breedveld, Margreet Baaijens, Nico Lanconelli, Ben Heijmen
PURPOSE AND OBJECTIVE: Propose a novel method for individualized selection of beam angles and treatment isocenter in tangential breast intensity modulated radiation therapy (IMRT). METHODS AND MATERIALS: For each patient, beam and isocenter selection starts with the fully automatic generation of a large database of IMRT plans (up to 847 in this study); each of these plans belongs to a unique combination of isocenter position, lateral beam angle, and medial beam angle...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28461256/smoking-history-predicts-sensitivity-to-parp-inhibitor-veliparib-in-patients-with-advanced-non-small-cell-lung-cancer
#13
Martin Reck, Normand Blais, Erzsebet Juhasz, Vera Gorbunova, C Michael Jones, Laszlo Urban, Sergey Orlov, Fabrice Barlesi, Ebenezer Kio, Ulrich Keilholz, Qin Qin, Jiang Qian, Caroline Nickner, Juliann Dziubinski, Hao Xiong, Rajendar K Mittapalli, Martin Dunbar, Peter Ansell, Lei He, Mark McKee, Vincent Giranda, Suresh S Ramalingam
INTRODUCTION: Tobacco-related non-small cell lung cancer (NSCLC) is associated with reduced survival and greater genomic instability. Veliparib, a potent PARP inhibitor, augments platinum-induced DNA damage. A phase 2 trial of untreated advanced NSCLC showed a trend for improved outcomes (overall survival [OS], HR 0.80, 95% CI: 0.54-1.18; p=0.27; and progression-free survival [PFS], HR 0.72, 95% CI: 0.45-1.15; p=0.17) when veliparib was added to carboplatin/paclitaxel. Here we report an exploratory analysis by smoking history...
April 28, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28460468/pd-l1-expression-and-its-relationship-with-oncogenic-drivers-in-non-small-cell-lung-cancer-nsclc
#14
Liyan Jiang, Xinying Su, Tianwei Zhang, Xiaolu Yin, Meizhuo Zhang, Haihua Fu, Hulin Han, Yun Sun, Lili Dong, Jialin Qian, Yanhua Xu, Xuan Fu, Paul R Gavine, Yanbin Zhou, Kun Tian, Jiaqi Huang, Dong Shen, Haiyi Jiang, Yihong Yao, Baohui Han, Yi Gu
In order to explore the potential patient population who could benefit from anti PD-1/PD-L1 mono or combination therapies, this study aimed to profile a panel of immunotherapy related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC.Tumor samples from 297 NSCLC patients, including 156 adenocarcinomas (AD) and 129 squamous cell carcinomas (SCC), were analyzed using immunohistochemistry, immunofluorescence, sequencing and fluorescence in situ hybridization...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28449093/opinions-of-lung-cancer-clinicians-on-shared-decision-making-in-early-stage-non-small-cell-lung-cancer%C3%A2
#15
Sahar Mokhles, Alex P W M Maat, Joachim G J V Aerts, Joost J M E Nuyttens, Ad J J C Bogers, Johanna J M Takkenberg
OBJECTIVES: To investigate the opinions of lung cancer clinicians concerning shared decision making (SDM) in early-stage non-small-cell lung cancer patients. METHODS: A survey was conducted among Dutch cardiothoracic surgeons and lung surgeons, pulmonologists and radiation oncologists. The opinions of clinicians on the involvement of patients in treatment decision making was assessed using a 1-5 Likert-type scale. Through open questions, we queried barriers to and drivers of SDM in clinical practice...
April 25, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/28444958/role-of-cytochrome-p450-3a4-and-1a2-phenotyping-in-patients-with-advanced-non-small-cell-lung-cancer-nsclc-receiving-erlotinib-treatment
#16
Zinnia P Parra-Guillen, Peter B Berger, Manuel Haschke, Massimiliano Donzelli, Daria Winogradova, Bogumila Pfister, Martin Früh, Charlotte Kloft, Stephan Krähenbühl, Silke Gillessen, Markus Joerger
Erlotinib is metabolized by cytochrome p450 (CYP) 3A and CYP1A. This study assessed CYP3A4 (midazolam) and CYP1A2 (caffeine) phenotyping in plasma and dried blood spots (DBS) for predicting the pharmacokinetics and toxicity of erlotinib in 36 patients with advanced NSCLC. On day 1, erlotinib 150 mg OD. was initiated, and the 2 oral probe drugs midazolam (2mg) and caffeine (100mg) were added on day 1. Plasma and DBS were collected for erlotinib, OSI-420 and probe drugs for up to 6 hr on day 1 and 2-weekly up to week 10...
April 26, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28442677/1-2-3-triazolyl-esterization-of-pak1-blocking-propolis-ingredients-artepillin-c-arc-and-caffeic-acid-ca-for-boosting-their-anti-cancer-anti-pak1-activities-along-with-cell-permeability
#17
Hideaki Takahashi, Binh Cao Quan Nguyen, Yoshihiro Uto, Md Shahinozzaman, Shinkichi Tawata, Hiroshi Maruta
Artepillin C (ARC) and caffeic acid (CA) are among the major anti-cancer ingredients of propolis, and block the oncogenic/melanogenic/ageing kinase PAK1. However, mainly due to their COOH moiety, cell-permeability of these herbal compounds is rather limited. Thus, in this study, in an attempt to increase their cell-permeability without any significant loss of their water-solubility, we have esterized both ARC and CA with the water-soluble 1,2,3-triazolyl alcohol through Click Chemistry. We found that this esterization boosts the anti-cancer activity of ARC and CA by 100 and over 400 folds, respectively, against the PAK-dependent growth of A549 lung cells, but show no effect on the PAK1-independent growth of B16F10 melanoma cells...
April 24, 2017: Drug Discoveries & Therapeutics
https://www.readbyqxmd.com/read/28440285/ionizing-radiation-abrogates-the-pro-tumorigenic-capacity-of-cancer-associated-fibroblasts-co-implanted-in-xenografts
#18
Maria Tunset Grinde, Jørg Vik, Ketil André Camilio, Inigo Martinez-Zubiaurre, Turid Hellevik
Cancer-associated fibroblasts (CAFs) are abundantly present in solid tumors and affect tumorigenesis and therapeutic responses. In the context of clinical radiotherapy, the impact of irradiated CAFs to treatment outcomes is largely unexplored. Aiming at improving radiotherapy efficacy, we have here explored the effect of radiation on the inherent pro-tumorigenic capacity of CAFs in animals. Ionizing radiation was delivered to cultured CAFs as single-high or fractionated doses. Tumor development was compared in mice receiving A549 lung tumor cells admixed with irradiated or control CAFs...
April 25, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28434943/epigenetic-pathways-in-human-disease-the-impact-of-dna-methylation-on-stress-related-pathogenesis-and-current-challenges-in-biomarker-development
#19
M Austin Argentieri, Sairaman Nagarajan, Bobak Seddighzadeh, Andrea A Baccarelli, Alexandra E Shields
HPA axis genes implicated in glucocorticoid regulation play an important role in regulating the physiological impact of social and environmental stress, and have become a focal point for investigating the role of glucocorticoid regulation in the etiology of disease. We conducted a systematic review to critically assess the full range of clinical associations that have been reported in relation to DNA methylation of CRH, CRH-R1/2, CRH-BP, AVP, POMC, ACTH, ACTH-R, NR3C1, FKBP5, and HSD11β1/2 genes in adults...
April 2017: EBioMedicine
https://www.readbyqxmd.com/read/28432037/investigating-in-vitro-and-in-vivo-%C3%AE-v%C3%AE-6-integrin-receptor-targeting-liposomal-alendronate-for-combinatory-%C3%AE-%C3%AE-t-cell-immunotherapy
#20
Naomi O Hodgins, Wafa' T Al-Jamal, Julie T-W Wang, Rebecca Klippstein, Pedro M Costa, Jane K Sosabowski, John F Marshall, John Maher, Khuloud T Al-Jamal
The αvβ6 integrin receptor has been shown to be overexpressed on many types of cancer cells, resulting in a more pro-invasive and aggressive phenotype, this makes it an attractive target for selective drug delivery. In tumours that over-express the αvβ6 receptor, cellular uptake of liposomes can be enhanced using ligand-targeted liposomes. It has previously been shown in both in vitro and in vivo studies that liposomal alendronate (L-ALD) can sensitise cancer cells to destruction by Vγ9Vδ2 T cells. It is hypothesised that by using the αvβ6-specific peptide A20FMDV2 as a targeting moiety for L-ALD, the therapeutic efficacy of this therapy can be increased in αvβ6 positive tumours...
April 18, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
keyword
keyword
117397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"